Drug profile · INN
dolutegravir + lamivudine
DOVATO
dolutegravir + lamivudine (DOVATO) is a human immunodeficiency virus type 1 integrase inhibitor. Associated with ViiV Healthcare Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — dolutegravir + lamivudine
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.81
Quick answer
dolutegravir + lamivudine (DOVATO) is a human immunodeficiency virus type 1 integrase inhibitor. Associated with ViiV Healthcare Pty Ltd.
Key facts
INN dolutegravir + lamivudine
Brand DOVATO
Mechanism Human immunodeficiency virus type 1 integrase inhibitor
Target Human immunodeficiency virus type 1 integrase
Originator ViiV Healthcare Pty Ltd
Mechanism of action
Human immunodeficiency virus type 1 integrase inhibitor
Primary target: Human immunodeficiency virus type 1 integrase
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dolutegravir + lamivudine?
dolutegravir + lamivudine (DOVATO) is a human immunodeficiency virus type 1 integrase inhibitor. Associated with ViiV Healthcare Pty Ltd.
What is the brand name for dolutegravir + lamivudine?
DOVATO is a marketed brand name for dolutegravir + lamivudine. Check FDA Drugs@FDA for the current US label holder and prescribing information.